Bermudez Jorge Antonio Zepeda, Esher Angela, Osorio-de-Castro Claudia Garcia Serpa, Vasconcelos Daniela Moulin Maciel de, Chaves Gabriela Costa, Oliveira Maria Auxiliadora, Silva Rondineli Mendes da, Luiza Vera Lucia
Departamento de Política de Medicamentos e Assistência Farmacêutica, Escola Nacional de Saúde Pública Sergio Arouca, Fiocruz. R. Leopoldo Bulhões 1480, Manguinhos. 21041-210 Rio de Janeiro RJ Brasil.
Cien Saude Colet. 2018 Jun;23(6):1937-1949. doi: 10.1590/1413-81232018236.09022018.
This article examines pharmaceutical services and access to essential medicines in Brazil during the 30 years since the advent of Brazil's Unified Health System from a comprehensiveness perspective. The following topics are addressed: the "realignment" of pharmaceutical services; human resources in pharmaceutical services; the essential medicines concept; the rational use of medicines; technological advances and drug manufacturing; and ethical regulation. With a strong regulatory focus and a structural framework centered on the National Medicines Policy, the past three decades represent a mixture of progress and setbacks, considering the national complexities of the healthcare system and the political, economic and social changes that have influenced policy and access to medicines, which is a key concern even in the world's richest countries, as the forums of discussion on global health have demonstrated. We show that major steps forward have been taken, highlighting that the recent fiscal austerity measures imposed by the government threaten to seriously undermine social progress.
本文从全面性角度审视了巴西统一卫生系统建立30年来该国的制药服务及基本药物获取情况。探讨了以下主题:制药服务的“重新调整”;制药服务中的人力资源;基本药物概念;药物的合理使用;技术进步与药品制造;以及伦理监管。鉴于过去三十年以国家药品政策为核心的强有力监管重点和结构框架,考虑到该国医疗体系的复杂性以及影响政策和药品获取的政治、经济和社会变革(正如全球卫生讨论论坛所表明的,这即使在世界最富裕国家也是一个关键问题),这三十年可谓是进步与挫折并存。我们表明已经取得了重大进展,同时强调政府最近实施的财政紧缩措施可能严重损害社会进步。